Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors applicable to Genprex’s Acclaim-2 and Acclaim-3 clinical trials
Reqorsa® Immunogene Therapy May be a Potential Therapy for ALK-Positive Lung Cancer
Three Collaborators Selected to Present Positive Nonclinical Data on Genprex Oncology Program at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes
Expects to Complete Enrollment of Phase 2a Expansion Study by the end of 2024
Genprex today announced that on February 2, 2024, the Company will implement a 1-for-40 reverse split of its issued and outstanding common stock, par value $0.001 per share.
Acclaim-1 Phase 2a and Acclaim-3 Phase 1 clinical studies opening for enrollment in January 2024 Poised for FDA guidance regarding diabetes gene therapy program in 2024
Presentation to be held on Tuesday, November 7, 2023 from 4:45 – 5:00 p.m. UTC
Designed and Secured by Barsec